Understanding High Blood Pressure

Despite decades of available treatments, uncontrolled hypertension remains one of the leading causes of preventable death worldwide. A 2021 analysis in The Lancet found that the number of adults with hypertension doubled between 1990 and 2019, reaching 1.28 billion people. Much of this increase has been attributed to rising obesity rates, particularly in middle-income countries.

The link between body weight and blood pressure is dose-dependent. For every 10 percent increase in body weight, systolic blood pressure rises by an average of 6.5 mmHg, based on longitudinal data from the Bogalusa Heart Study. This relationship works in reverse too: significant weight loss consistently produces meaningful blood pressure drops, which is where medications like Zepbound enter the picture.

Conventional blood pressure drugs (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics, and beta-blockers) remain the backbone of treatment. But they address the downstream problem (elevated pressure in the arteries) rather than the upstream cause (in many patients, excess weight and its metabolic consequences). types of blood pressure medications

What the Research Shows

SURMOUNT-1: The Weight Management Trial

The SURMOUNT-1 trial, published by Jastreboff et al. in the New England Journal of Medicine in 2022, remains the most comprehensive dataset for Zepbound and blood pressure. Among 2,539 adults with obesity (mean BMI 38), tirzepatide at the 15 mg dose reduced systolic blood pressure by 7.2 mmHg compared to 1.0 mmHg with placebo at week 72.

A subgroup analysis of SURMOUNT-1 by Aronne et al. examined participants who had hypertension at baseline. In this subgroup, the 15 mg dose reduced systolic blood pressure by 10.6 mmHg, nearly double the reduction seen in the overall population. This finding suggests that patients with the most to gain see the largest improvements.

SURMOUNT-2: Patients with Type 2 Diabetes

SURMOUNT-2 enrolled patients who had both obesity and type 2 diabetes, a population where hypertension is nearly ubiquitous. Garvey et al. reported in The Lancet in 2023 that tirzepatide reduced systolic blood pressure by 6.4 mmHg at the 15 mg dose over 72 weeks, compared to 1.4 mmHg with placebo.

Importantly, many SURMOUNT-2 participants were already taking antihypertensive medications, yet tirzepatide still provided additional blood pressure lowering on top of those existing treatments.

SURMOUNT-MMO: The Ongoing Cardiovascular Outcomes Trial

Eli Lilly is currently conducting SURMOUNT-MMO, a major cardiovascular outcomes trial that will directly measure whether tirzepatide reduces heart attacks, strokes, and cardiovascular death. This trial enrolled approximately 15,000 adults with obesity and established cardiovascular disease or multiple risk factors. Results are expected around 2027.

How Zepbound May Help

Zepbound is the brand name for tirzepatide when prescribed for weight management. It is a dual-action peptide that activates both GLP-1 and GIP receptors, producing effects that go beyond what either receptor alone can achieve. what is Zepbound

For blood pressure, Zepbound's primary advantage is the sheer magnitude of weight loss it produces. At the 15 mg dose, patients in SURMOUNT-1 lost an average of 22.5 percent of body weight, more than any other approved medication. Since the blood pressure-weight relationship is roughly linear (about 1 mmHg per kg lost), this degree of weight loss has enormous potential to normalize blood pressure in patients with obesity-driven hypertension.

The dual GIP/GLP-1 mechanism may also contribute unique metabolic benefits. GIP receptor activation has been shown to improve fat metabolism and reduce ectopic fat deposition (fat stored in organs like the liver and around blood vessels). Research by Samms et al. in Cell Metabolism demonstrated that GIP signaling in adipose tissue promotes healthier fat storage and reduces the inflammatory signals that contribute to vascular dysfunction.

Zepbound also markedly improves insulin sensitivity. In SURMOUNT-1, measures of insulin resistance (HOMA-IR) improved by approximately 60 percent with the 15 mg dose. Since insulin resistance drives sodium retention and sympathetic overactivity, reversing it can produce substantial blood pressure benefits.

Important Safety Information

Zepbound is FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity. It does not have an FDA-approved indication for blood pressure reduction.

Gastrointestinal side effects are the most frequently reported: nausea (24 to 33 percent), diarrhea (17 to 23 percent), vomiting (7 to 12 percent), and constipation (12 to 17 percent), depending on dose. Gradual dose titration over 20 weeks helps minimize these effects.

Zepbound carries a boxed warning about thyroid C-cell tumors observed in animal studies. It is contraindicated in patients with medullary thyroid carcinoma or MEN2.

Other risks include pancreatitis, gallbladder disease (gallstones occur more frequently during rapid weight loss), and potential worsening of diabetic retinopathy in patients with diabetes. Patients on blood pressure medications should be monitored for hypotension as weight drops. Zepbound safety profile

Who Might Benefit

The patient profile most likely to see blood pressure improvements with Zepbound includes:

• Adults with a BMI of 30 or higher whose hypertension is largely attributable to excess weight
• Patients with treatment-resistant hypertension (uncontrolled on three or more medications) where obesity is a contributing factor
• People who need substantial weight loss (15 percent of body weight or more) and whose blood pressure would benefit from that degree of weight change
• Individuals with metabolic syndrome who want to address multiple risk factors with a single intervention

Zepbound is not appropriate as a first-line blood pressure treatment for patients at a healthy weight. It is also not a substitute for proven antihypertensive medications in patients with acute or severe hypertension requiring immediate control.

How to Talk to Your Doctor

If you are interested in Zepbound for its potential blood pressure benefits, consider approaching the discussion from the standpoint of comprehensive cardiometabolic health:

• Share your weight history and explain how excess weight may be contributing to your blood pressure challenges
• Mention the SURMOUNT trial results showing blood pressure reductions, particularly in patients with baseline hypertension
• Ask whether you are a candidate based on your BMI and comorbidity profile
• Discuss a monitoring plan for blood pressure as weight loss progresses, including potential adjustments to existing medications

Be aware that Zepbound's list price is significant, and insurance coverage varies widely. Your provider's office may be able to help navigate prior authorization or connect you with manufacturer savings programs. affording GLP-1 medications

Frequently Asked Questions

How does Zepbound compare to Wegovy for blood pressure?

Both medications lower blood pressure effectively. Zepbound (tirzepatide) tends to produce slightly greater weight loss than Wegovy (semaglutide 2.4 mg) in clinical trials, which may translate to somewhat larger blood pressure reductions. However, Wegovy has completed a large cardiovascular outcomes trial (SELECT) that confirmed reduced heart attack and stroke risk, while Zepbound's corresponding trial (SURMOUNT-MMO) is still ongoing.

Will Zepbound lower my blood pressure if I am not overweight?

Zepbound is only approved for patients with a BMI of 27 or higher. Its blood pressure effects are primarily mediated through weight loss and metabolic improvement. For patients at a healthy weight, standard antihypertensive medications are the appropriate treatment.

Can Zepbound cause low blood pressure?

In patients who lose a significant amount of weight while also taking blood pressure medications, blood pressure can drop below target. Symptoms might include dizziness, lightheadedness, or fatigue. This is why regular blood pressure monitoring during Zepbound treatment is important. Your doctor can adjust your other medications as needed.

Taking the Next Step

Zepbound's combination of substantial weight loss and metabolic improvement positions it as a powerful tool for patients whose hypertension is rooted in obesity. As we await the results of the SURMOUNT-MMO cardiovascular outcomes trial, the evidence from SURMOUNT-1 and SURMOUNT-2 already paints a compelling picture.

At FormBlends, we keep you informed about the latest developments in GLP-1 and GIP therapy. Explore our resources and bring what you have learned to your next conversation with your healthcare provider. GLP-1 medications overview